AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) is experiencing that most beloved of conditions for any company: people are competing to throw money at the company for equity interest. After announcing and then increasing a bought-deal financing a few days ago, which is essentially like an IPO that doesn’t even go to market because the IB buys all the stock, the company just hit the wires with a new chapter to the narrative.

Aurora just announced, as we discussed, the $60 million bought deal financing (announced and upsized on October 10, 2017). However, now, the Company has agreed to a one-time special accommodation for the benefit of its underwriters due to very significant demand for the Bought Deal, to proceed with a concurrent, non-commissioned, non-brokered private placement of up to 2,000,000 units of the Company at a price of $3.00 per Unit. Note that this price is well above the market. That’s unusual, and continues the bullish theme.

AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) is a licensed producer of medical marijuana pursuant to the Marijuana for Medical Purposes Regulations and operates a 55,200 square foot expandable state-of-the-art production facility in Alberta, Canada.

ACBFF’s wholly-owned subsidiary, Australis Capital Inc., seeks to be an active participant in the U.S. Cannabis market. Aurora is trading on the Canadian Securities Exchange under the trading symbol “ACB”. The company is headquartered in Vancouver, Canada.

FREE CONFIDENTIAL REPORT 3 Stocks Set To Soar By October 1st, 2020 SUBSCRIBE! You have Successfully Subscribed!

According to company’s materials, “Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, is currently constructing a second 800,000 square foot production facility, known as “Aurora Sky”, at the Edmonton International Airport, and has acquired, and is undertaking completion of a third 40,000 square foot production facility in Pointe-Claire, Quebec, on Montreal’s West Island. In addition, the Company holds approximately 9.6% of the issued shares (12.9% on a fully-diluted basis) in leading extraction technology company Radient Technologies Inc., based in Edmonton, and is in the process of completing an investment in Edmonton-based Hempco Food and Fiber for an ownership stake of up to 50.1%. Furthermore, Aurora is the cornerstone investor with a 19.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis. Aurora also owns Pedanios, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union (“EU”), based in Germany.”

Find out when $ACBFF reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

As noted above, the company is having a hard time turning interest away right now. The Bought Deal financing had to be increased at a price above prevailing market levels, and now the company is extending share availability in the same direction to those underwriting the recent move.

It’s an unusual state of affairs and seems to highlight the demand right now to gain access to exposure in this space.

According to the recent release, “If the Offering is subscribed for in full, it will provide Aurora with net proceeds of $6,000,000 due to the special and one-time commission free accommodation reached with its underwriters. The Common Shares and Warrants shall be subject to a 4 month hold period. Closing of the Offering is anticipated to occur at the same time as the closing of the Bought Deal, which is expected on or about November 2, 2017, and is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Toronto Stock Exchange and the applicable securities regulatory authorities.”

Currently trading at a market capitalization of $819M, ACBFF has a significant war chest ($159.8M) of cash on the books, which is balanced by virtually no total current liabilities. ACBFF is pulling in trailing 12-month revenues of $18.1M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 386.5%. We will update the story again soon as developments transpire. Sign-up for continuing coverage on shares of $ACBFF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $ACBFF, either long or short, and we have not been compensated for this article.